CANTHARIDIN - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for cantharidin and what is the scope of patent protection?
Cantharidin
is the generic ingredient in one branded drug marketed by Verrica Pharms and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Cantharidin has sixty-six patent family members in eleven countries.
One supplier is listed for this compound.
Summary for CANTHARIDIN
| International Patents: | 66 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 78 |
| Clinical Trials: | 20 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CANTHARIDIN |
| What excipients (inactive ingredients) are in CANTHARIDIN? | CANTHARIDIN excipients list |
| DailyMed Link: | CANTHARIDIN at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CANTHARIDIN
Generic Entry Date for CANTHARIDIN*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
SOLUTION;TOPICAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for CANTHARIDIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Queen Mary University of London | N/A |
| Medical Research Council | N/A |
| Medical University of South Carolina | Phase 4 |
US Patents and Regulatory Information for CANTHARIDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verrica Pharms | YCANTH | cantharidin | SOLUTION;TOPICAL | 212905-001 | Jul 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Verrica Pharms | YCANTH | cantharidin | SOLUTION;TOPICAL | 212905-001 | Jul 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Verrica Pharms | YCANTH | cantharidin | SOLUTION;TOPICAL | 212905-001 | Jul 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Verrica Pharms | YCANTH | cantharidin | SOLUTION;TOPICAL | 212905-001 | Jul 21, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CANTHARIDIN
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 2025013334 | 皮膚障害の処置のための組成物、方法、およびシステム (COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERS) | ⤷ Start Trial |
| Spain | 2986887 | ⤷ Start Trial | |
| Japan | 2022137132 | 皮膚障害の処置のための組成物、方法、およびシステム | ⤷ Start Trial |
| Australia | 2021202518 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
